tbuckley/cabot-search huggingface dataset:
P2.16-34 Is Prophylactic Cranial Irradiation Useful in Real World?
Authors: R. Gómez Bravo, B. Núñez-García, J. Sánchez González, C. Alfaro Autor, B. De La Puente Orteu, A. Royuela, M. Méndez García, B. Cantos Sánchez De Ibarguen, V. Calvo De Juan, M. Provencio
Journal: Journal of Thoracic Oncology (2019)
Dose-intensive cyclophosphamide, etoposide, cisplatin reinduction for relapsed/refractory aggressive non-Hodgkin lymphoma (r/r-aNHL).
Authors: Jan-Willem Henning, Qiuli Duan, Nizar J. Bahlis, Andrew Daly, Peter Duggan, Mona Shafey, Douglas Allan Stewart
Journal: Journal of Clinical Oncology (2012)

6548 Background: Approximately 2/3 r/r-aNHL patients (pts) respond to salvage R-ICE or R-DHAP, 1/2 proceed to autologous stem cell transplantation (ASCT), and 1/3 achieve 3 year (yr) progression-free survival (PFS); however, PFS is only 20% if prior Rituximab, time to progression (TTP)&lt;1yr, or age-adjusted International Prognostic Index (aaIPI)=2-3 [JCO 2010;28: 4184-90]. Since 1995, we re-induced poor prognosis r/r-aNHL with dose-intensive Cyclophosphamide 5.25g/m 2 , Etoposide 1.05g/m 2 and Cisplatin 105mg/m 2 (DICEP), G-CSF days (d) 14-19, and apheresis d19,20, or 21. Rituximab was added d0,7 after 2006. Methods: We retrospectively analyzed 113 consecutive transplant eligible r/r-aNHL pts [diffuse large B-cell=95, transformed=9, peripheral T-cell=6, other=3] who received one cycle of DICEP (n=93) or R-DICEP (n=20) from 1995-2009. Patient characteristics included: median age=49yr (22-69); primary refractory=68; TTP&lt;1yr=85; elevated LDH=60; ECOG 2-4=42; aaIPI 2-3=59; bulk&gt;10cm=26. Results: Of 113 pts, 77% responded to DICEP and 90% (102) proceeded to ASCT. The median CD34+ cells collected was 19x10 6 /kg (0.3-142). Early treatment-related mortality (TRM) occurred in 3 pts (2.7%), and 4 others developed late second cancers (MDS/AML=2). With 94 months median follow-up (26-194), 5 and 10yr OS rates for all 113pts are 48% and 41%, and PFS rates are 42% and 37%, respectively. 5 year PFS rates for ASCT vs no-ASCT are 46% vs 9%, for relapse aaIPI=0-1 vs aaIPI=2-3 are 53.3% vs 32.1% (p=0.01), and for TTP&gt;1yr vs &lt;1yr are 63.9% vs 35.2% (p=0.009). Other predictors of inferior PFS in univariate analysis were elevated LDH, ECOG 2-4, no response to DICEP; however, PFS for 27 pts who failed prior Rituximab-chemotherapy (56%) was similar to other 86 pts (38%) (logrank p=0.09). Predictors of PFS and OS in multivariate analysis include: TTP&lt;1yr, elevated LDH, bulk, no response to DICEP. Conclusions: (R)DICEP is an effective re-induction regimen for r/r-aNHL, leading to excellent stem cell mobilization and a high chance of proceeding to ASCT. Long-term PFS and OS rates compare favourably to reports of other re-induction regimens, and a prospective multicentre trial is warranted.
Disparities in Maternal Mortality
Authors: Bridget Kuehn
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reliable Confidence Intervals for RelTime Estimates of Evolutionary Divergence Times
Authors: Qiqing Tao, Koichiro Tamura, Beatriz Mello, Sudhir Kumar
Journal: Molecular Biology and Evolution (2019)

Abstract Confidence intervals (CIs) depict the statistical uncertainty surrounding evolutionary divergence time estimates. They capture variance contributed by the finite number of sequences and sites used in the alignment, deviations of evolutionary rates from a strict molecular clock in a phylogeny, and uncertainty associated with clock calibrations. Reliable tests of biological hypotheses demand reliable CIs. However, current non-Bayesian methods may produce unreliable CIs because they do not incorporate rate variation among lineages and interactions among clock calibrations properly. Here, we present a new analytical method to calculate CIs of divergence times estimated using the RelTime method, along with an approach to utilize multiple calibration uncertainty densities in dating analyses. Empirical data analyses showed that the new methods produce CIs that overlap with Bayesian highest posterior density intervals. In the analysis of computer-simulated data, we found that RelTime CIs show excellent average coverage probabilities, that is, the actual time is contained within the CIs with a 94% probability. These developments will encourage broader use of computationally efficient RelTime approaches in molecular dating analyses and biological hypothesis testing.
P2.04-02 Effect of Chemotherapy, Chemoimmunotherapy, and Immunotherapy on Parameters of T Cell Exhaustion in Metastatic Non-Small Cell Lung Cancer
Authors: J. Bauml, D. Yoon, P. Yan, S. Katz, S. Jeffries, C. Davis, C. Aggarwal, R. Cohen, M. Marmarelis, A. Singh, C. Ciunci, E. Wherry, S. Albelda, C. Langer, A. Huang
Journal: Journal of Thoracic Oncology (2019)
P2.03-08 Analysis of Immunosuppressive Factors Produced by CSCs Revealed Galectin-3 as Immune Modulator with Prognostic Value in NSCLC Adenocarcinoma
Authors: S. Torres, A. Herreros-Pomares, F. Zhang, S. Calabuig-Fariñas, R. Sirera, M. Mosqueda, E. Escorihuela, Á. González, N. Dong, S. Gallach, J. Garde, R. Guijarro, E. Jantus-Lewintre, C. Camps
Journal: Journal of Thoracic Oncology (2019)
Vertebral Fractures in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone
Authors: Fjorda Koromani, Ling Oei, Enisa Shevroja, Katerina Trajanoska, Josje Schoufour, Taulant Muka, Oscar H. Franco, M. Arfan Ikram, M. Carola Zillikens, André G. Uitterlinden, Gabriel P. Krestin, Tassos Anastassiades, Robert Josse, Stephanie M. Kaiser, David Goltzman, Brian C. Lentle, Jerilynn C. Prior, William D. Leslie, Eugene McCloskey, Olivier Lamy, Didier Hans, Edwin H. Oei, Fernando Rivadeneira
Journal: Diabetes Care (2019)

OBJECTIVE We aimed to assess whether individuals with type 2 diabetes (T2D) have increased risk of vertebral fractures (VFs) and to estimate nonvertebral fracture and mortality risk among individuals with both prevalent T2D and VFs. RESEARCH DESIGN AND METHODS A systematic PubMed search was performed to identify studies that investigated the relationship between T2D and VFs. Cohorts providing individual participant data (IPD) were also included. Estimates from published summary data and IPD cohorts were pooled in a random-effects meta-analysis. Multivariate Cox regression models were used to estimate nonvertebral fracture and mortality risk among individuals with T2D and VFs. RESULTS Across 15 studies comprising 852,705 men and women, individuals with T2D had lower risk of prevalent (odds ratio [OR] 0.84 [95% CI 0.74–0.95]; I2 = 0.0%; Phet = 0.54) but increased risk of incident VFs (OR 1.35 [95% CI 1.27–1.44]; I2 = 0.6%; Phet = 0.43). In the IPD cohorts (N = 19,820), risk of nonvertebral fractures was higher in those with both T2D and VFs compared with those without T2D or VFs (hazard ratio [HR] 2.42 [95% CI 1.86–3.15]) or with VFs (HR 1.73 [95% CI 1.32–2.27]) or T2D (HR 1.94 [95% CI 1.46–2.59]) alone. Individuals with both T2D and VFs had increased mortality compared with individuals without T2D and VFs (HR 2.11 [95% CI 1.72–2.59]) or with VFs alone (HR 1.84 [95% CI 1.49–2.28]) and borderline increased compared with individuals with T2D alone (HR 1.23 [95% CI 0.99–1.52]). CONCLUSIONS Based on our findings, individuals with T2D should be systematically assessed for presence of VFs, and, as in individuals without T2D, their presence constitutes an indication to start osteoporosis treatment for the prevention of future fractures.
Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T <sub>reg</sub> cells by inhibition of CDK8/19
Authors: Masahiko Akamatsu, Norihisa Mikami, Naganari Ohkura, Ryoji Kawakami, Yohko Kitagawa, Atsushi Sugimoto, Keiji Hirota, Naoto Nakamura, Satoru Ujihara, Toshio Kurosaki, Hisao Hamaguchi, Hironori Harada, Guliang Xia, Yoshiaki Morita, Ichiro Aramori, Shuh Narumiya, Shimon Sakaguchi
Journal: Science Immunology (2019)

CDK8/19 inhibitors can convert naïve and memory/effector T cells into T reg cells capable of treating immunological diseases.
P2.17-29 Impact of Second Predominant Pattern on Recurrence in Early Stage Resected Lung Adenocarcinoma: A Multicentric Study
Authors: P. Bertoglio, M. Cattoni, D. Nachira, F. Lococo, V. Aprile, M. Rodriguez, F. Guerrera, F. Franzi, A. Viti, S. Bellafiore, G. Rindi, D. Bacchin, M.D. Lozano Escario, F. Femia, G. Querzoli, L. Garcia Tobar, E. Ruffini, M. Paci, S. Margaritora, M. Lucchi, A. Imperatori, A. Terzi
Journal: Journal of Thoracic Oncology (2019)
HOPS: a quantitative score reveals pervasive horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of human traits and diseases
Authors: Daniel M. Jordan, Marie Verbanck, Ron Do
Journal: Genome biology (2019)

Horizontal pleiotropy, where one variant has independent effects on multiple traits, is important for our understanding of the genetic architecture of human phenotypes. We develop a method to quantify horizontal pleiotropy using genome-wide association summary statistics and apply it to 372 heritable phenotypes measured in 361,194 UK Biobank individuals. Horizontal pleiotropy is pervasive throughout the human genome, prominent among highly polygenic phenotypes, and enriched in active regulatory regions. Our results highlight the central role horizontal pleiotropy plays in the genetic architecture of human phenotypes. The HOrizontal Pleiotropy Score (HOPS) method is available on Github at https://github.com/rondolab/HOPS .
Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)
Authors: Henk Lokhorst, Bronno van der Holt, Sonja Zweegman, Peter A. Von Dem Borne, Gerard M.J. Bos, Sandra Croockewit, Jan J. Cornelissen, Marinus van Oers, Martyn Ronald Schaafsma, Harm Sinnige, Michel Delforge, Okke de Weerdt, Pierre W Wijermans, Shulamiet Wittebol, Edo Vellenga, Asiong Jie, Henriette Berenschot, Marinus Marwijk-kooy, Pieter Sonneveld
Journal: Blood (2008)
P1.04-55 Comparison of PD-L1 Expression Status Between Pure-Solid Versus Part-Solid Tumors in Lung Adenocarcinomas
Authors: K. Suda, S. Shimizu, M. Shimoji, K. Sato, S. Ohara, T. Fujino, M. Nishino, T. Koga, A. Hamada, K. Tomizawa, T. Takemoto, J. Soh, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2019)
P2.17-21 A Post-Hoc Analysis of TROG 09.02 (CHISEL) Phase III Trial Investigating Pulmonary Function Changes After SABR and Conformal Radiation Therapy
Authors: N. Bucknell, T. Kron, A. Herschtal, L. Irving, S. Siva, D. Ball
Journal: Journal of Thoracic Oncology (2019)
EP1.04-46 Immunotherapy at Any Line Improves Survival in Hispanic Patients with Advanced Metastatic NSCLC Compared to Chemotherapy (Quijote-CLICaP)
Authors: A.F. Cardona, A. Ruiz-Patiño, O.G. Arrieta, C. Martin, L. Raez, Z.L. Zatarain Barrón, F. Barrón, L. Ricaurte, M.A. Bravo-Garzón, L. Mas, L. Corrales, L.L. Rojas, L. Lupinacci, F. Perazzo, C. Bas, O. Carranza, C. Puparelli, M. Rizzo, R. Ruiz, C. Rolfo, P. Archila, J. Rodriguez, C. Sotelo, C. Vargas, H. Carranza, J. Otero, L. Pino, C. Ortiz, P. Laguado, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
Pulmonary hypertension after bone marrow transplantation in children
Authors: Marilyne Levy, Despina Moshous, Isabelle Szezepanski, Louise Galmiche, Martin Castelle, Fabrice Lesage, Laurent Dupic, Bénédicte Neven, Alain Fischer, Stéphane Blanche, Damien Bonnet
Journal: European Respiratory Journal (2019)

Pulmonary hypertension is a rare but important cause of mortality after haematopoietic stem cell transplantation (HSCT) in children. This complication is poorly characterised in the literature. We report here a series of children who developed pulmonary hypertension after HSCT.Between January 2008 and December 2015, we retrospectively analysed 366 children who underwent HSCT (age range 0.5-252 months; median 20.3 months). During the post-HSCT course, echocardiography scans motivated by respiratory symptoms identified 31 patients with elevated tricuspid regurgitation velocity (>2.8 m·s-1), confirmed when possible by right heart catheterisation (RHC).22 patients had confirmed pulmonary hypertension with mean±sd pulmonary arterial pressure 40.1±10 mmHg (range 28-62 mmHg) and pulmonary vascular resistance 17.3±9.2 Wood Units (range 8-42 Wood Units). Among the 13 responders at reactivity test, only one patient responded to calcium channel blockers. Seven patients (32%) died. 15 pulmonary hypertension patients were alive after a mean±sd follow-up of 6.5±2.3 years (range 2-10 years). All survivors could be weaned off pulmonary hypertension treatment after a median follow-up of 5 months (range 3-16). The delay between clinical symptoms and initiation of pulmonary hypertension therapy was significantly longer in patients who subsequently died (mean±sd 33.5±23 days; median 30 days) than in survivors (mean±sd 7±3 days) (p<0.001).Pulmonary hypertension is a severe complication of HSCT with an underestimated incidence and high mortality. Aggressive and timely up-front combination therapy allowed normalisation of pulmonary pressure and improved survival.
EP1.03-14 Clinicopathologic Characteristics and Outcomes of Chinese Patients with Non-Small-Cell Lung Cancer and INPP4B Mutations
Authors: D. Yang, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Z. Huang, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
Five podcasts every medical student should listen to
Authors: Anna-Lucia Koerling
Journal: BMJ (2019)

From case studies to historical tales, Annie Koerling lists her favourite medical podcasts Podcasts are fast gaining popularity, particularly among young people. There's a dizzying array to choose from—with over 700 000 shows and 29 million episodes available online as of August 2019.1 Not only can you find a podcast on nearly every imaginable topic, but (with a few exceptions) they're free to download. BMJ Student makes a podcast for medical students and newly qualified doctors, Sharp Scratch (bmj.com/sharpscratch), and there are hundreds of other medical podcasts on Apple podcasts. A lot are very specialised—ideal for consultants and registrars making difficult management decisions, but not always relevant for medical students. To make life easier for you, I sampled about 30 medical podcasts and picked out five great podcasts to make that long commute to placement a bit easier.
Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine
Authors: Nicolas F. Schlecht, Martin Masika, Angela Diaz, Anne Nucci-Sack, Anthony Salandy, Sarah Pickering, Howard D. Strickler, Viswanathan Shankar, Robert D. Burk
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, and oral HPV infection is associated with increased risk of oropharyngeal cancer. <h3>Objective</h3> To describe the risk factors for oral HPV in sexually active female adolescents receiving the quadrivalent vaccine. <h3>Design, Setting, and Participants</h3> Longitudinal cohort study involving repeated collection of oral rinse specimens from sexually active female adolescents conducted between October 19, 2007, and March 9, 2017, at a large adolescent health center in New York, New York, that provides free health care, including HPV vaccination. <h3>Exposures</h3> Human papillomavirus vaccination and self-reported history of sexual behavior. <h3>Main Outcomes and Measures</h3> Prevalence of HPV in the oral cavity. <h3>Results</h3> Among the 1259 participants who were included in this study, median age at entry into the study was 18 (range, 13-21) years; 638 (50.7%) were of African American descent, 569 (45.2%) were of Hispanic descent, 43 (3.4%) reported another race/ethnicity, and race/ethnicity was unspecified for 9 (0.7%). The median (mode) age at first sexual activity was 14.8 (14) years, and 1161 (92.2%) reported having had oral sex. Human papillomavirus DNA was detected in baseline oral rinse samples of 78 of the 1259 participants (6.2%; 95% CI, 4.9%-7.6%). There was a significant decrease in oral HPV detection with time (in years) since first engaging in sexual activities, independent of age and concurrent detection of cervical HPV; comparing 4 or more years with 1 year or less, the odds ratio was 0.45 (95% CI, 0.21-0.96). Detection of vaccine types (HPV-6, HPV-11, HPV-16, and HPV-18) was significantly lower among participants who had received at least 1 dose of the quadrivalent HPV vaccine at the time of enrollment compared with those who were unvaccinated (odds ratio, 0.20; 95% CI, 0.04-0.998). <h3>Conclusions and Relevance</h3> This study's findings suggest that detection of HPV in the oral cavity is not uncommon in sexually active female adolescents. In addition, HPV vaccination is associated with a significant decrease in detection of HPV vaccine types in the oral cavity.
P2.04-65 Peptide-Based Cancer Vaccine Shortened the Overall Survival of a Large Portion, but Not All, of Advanced Cancer Patients
Authors: K. Yoshiyama, M. Noguchi, M. Terasaki, S. Sugawara, A. Yamada, S. Shichijo, S. Takamori, Y. Akagi, S. Yutani, K. Itoh
Journal: Journal of Thoracic Oncology (2019)
P2.16-15 Survival and Clinical Immunotherapy Outcomes in Hispanic Patients vs Non-Hispanic White Patients with Non-Small Cell Lung Cancer
Authors: L. Raez, D. Saravia, D. Sumarriva, R. Ruiz, P. Izquierdo, D. Cress, B. Hunis, L. Mas, G. Lopes, D. Kaen
Journal: Journal of Thoracic Oncology (2019)
Pretransplant comorbidity as an outcome predictor in adult patients younger than 60 years of age receiving standard induction chemotherapy for de novo acute myeloid leukemia
Authors: S. Kim, J. Lee, J. Lee, D. Kim, S. Lim, Y. Lee, Y. Kang, M. Seol, S. Ryu, K. Lee
Journal: Journal of Clinical Oncology (2009)

7055 Background: Comorbidity has been evaluated as an outcome predictor in elderly patients receiving induction chemotherapy for acute myeloid leukemia (AML) as well as in patients undergoing allogeneic hematopoietic cell transplantation (HCT) for various hematologic disorders. In this single-institute retrospective study, we investigated the prognostic significance of comorbidity in younger AML patients. Methods: A total of 276 patients, aged 14 to 59 years, who received standard induction chemotherapy consisting of cytarabine plus daunorubicin or idarubicin for de novo AML excluding M3 subtype between 2000 and 2007 were included. Pre-treatment comorbidity score, assessed by the HCT specific comorbidity index (HCT-CI), was calculated using clinico- pathologic data, which were retrieved from Asan Medical Center Leukemia Registry Database. The HCT-CI score was 0 in 113 patients (40.9%), 1 in 94 (34.1%), and ≥ 2 in 69 (25.0%). Results: In the univariate analyses, the HCT-CI score was not a significant prognostic factor for induction of complete remission (CR), whereas survival outcomes such as overall survival (OS), relapse-free survival (RFS) and event-free survival (EFS) were significantly different according to the HCT-CI scores (Table). The multivariate models showed that the HCT-CI score was an independent prognostic factor for EFS (P=0.044), but not for OS (P=0.301) and RFS (P=0.119). Other independent prognostic factors were age (P=0.001 for OS, P=0.002 for RFS, P=0.006 for EFS), initial leukocyte counts (P=0.006 for CR, P&lt;0.001 for OS, P=0.039 for RFS), initial uric acid levels (P=0.004 for RFS, P=0.001 for EFS), and cytogenetic risk groups (P=0.012 for CR, P&lt;0.001 for OS, P&lt;0.001 for RFS, P=0.005 for EFS). Conclusions: Pre-treatment comorbidity may provide additional prognostic information over established prognostic factors in patients younger than 60 years of age receiving standard induction chemotherapy for de novo AML. [Table: see text] No significant financial relationships to disclose.
EP1.14-05 Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
Authors: T. Yamada, A. Yoshimura, T. Takeda, S. Shiotsu, O. Hiranuma, Y. Chihara, J. Uchino, K. Takayama
Journal: Journal of Thoracic Oncology (2019)
P1.01-86 Occurrence of de Novo Dual HER2/HER3 or HER2/EGFR TMD Mutations: Extending the Spectrum of Targetable Mono-HER2 TMD in NSCLC?
Authors: S. Ou, A. Schrock, E. Bocharov, J. Lee, R. Madison, L. Gay, V. Miller, B. Alexander, H. Husain, J. Riess, S. Ali, V. Velcheti
Journal: Journal of Thoracic Oncology (2019)
P2.03-48 Tumor-Derived Granulocyte Chemotactic Protein 2 Cooperates with Proteases to Drive Lung Adenocarcinoma
Authors: A.S. Lamort, M. Pepe, I. Lilis, S.A. Weiß, K. Arendt, G. Ntaliarda, M. Spella, D. Jenne, G. Stathopoulos
Journal: Journal of Thoracic Oncology (2019)
The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Authors: Peter Hillmen, Petra Muus, Ulrich Dührsen, Antonio M. Risitano, Jörg Schubert, Neal S. Young, Hubert Schrezenmeier, Jeffrey Szer, Robert A. Brodsky, Anita Hill, Gérard Socié, Scott A. Rollins, Russell P. Rother, Leonard Bell, Lucio Luzzatto
Journal: Blood (2006)
P2.17-10 Effects of the Omega-6/Omega-3 Ratio on Postoperative Complications After Lung Resection: Preliminary Results
Authors: C. Deniz, R. Ramos, I. Macía, F. Rivas, A. Ureña, G. Rosado, P. Rodriguez-Taboada, S. Aso-González, S. Padrones-Sánchez, I. Escobar
Journal: Journal of Thoracic Oncology (2019)
A27 Stage I Lung Adenocarcinoma Gene Expression Associated with Aggressive Histologic Features for Guiding Precision Surgery and Therapy
Authors: J. Zhang, E. Burks, T. Sullivan, J. Sands, S. Regis, B. McKee, A. McKee, S. Zhang, H. Liu, G. Liu, S. Dubinett, A. Spira, J. Beane, K. Rieger-Christ, M. Lenburg
Journal: Journal of Thoracic Oncology (2020)
MA15.02 Deep Learning Approach for Automated Tumor Cells Detection and Estimation of PD-L1 22C3 Assay Expression in Lung Adenocarcinoma
Authors: D. Lin, J. Wu, W. Sun, C. Liu, X. Liu, Y. Zhang, J. Zhang, H. Wang, X. Liu, X. Yang, S. Ling
Journal: Journal of Thoracic Oncology (2019)
P2.16-11 ADVANCE-1: Development and Feasibility Testing of a Benchmarking Approach for Quality Improvement in Lung Cancer Care
Authors: B. Mccann, R. Muhr, N. O'Rourke, T. Blum, R. Milroy, D. Morrison, J. Kollmeier, D. Misch, J. Van Der Horst, B. Sens, O. Massalski, T. Bauer
Journal: Journal of Thoracic Oncology (2019)